File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/S0732-8893(98)00139-4
- Scopus: eid_2-s2.0-0032939481
- PMID: 10342100
- WOS: WOS:000080305100001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and E-test
Title | Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and E-test |
---|---|
Authors | |
Issue Date | 1999 |
Publisher | Elsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/diagmicrobio |
Citation | Diagnostic Microbiology and Infectious Disease, 1999, v. 34 n. 1, p. 1-6 How to Cite? |
Abstract | A prospective study on the susceptibility of Clostridium difficile to metronidazole and vancomycin using the Etest and disk diffusion test was performed over a 6-month period. One hundred strains were tested; one strain was highly resistant to metronidazole (MIC = 64 μg/mL). The zone size of inhibition by the disk diffusion test correlated with the MIC as determined by the Etest (regression coefficient = -0.043 for metronidazole and -0.044 for vancomycin, p < 0.001 for both antibiotics). However, the correlation coefficient was low for both metronidazole (r = 0.574) and vancomycin (r = 0.473); hence the zone of inhibition by disk diffusion test could not predict the MIC satisfactorily. Metronidazole is still the first-line antibiotic for the treatment of C. difficile-associated diarrhea because the incidence of metronidazole resistant strains remains very low. However, the efficacy of metronidazole in the treatment of infections attributable to isolates with high-level metronidazole resistance may be compromised because the fecal concentration of metronidazole is relatively low when compared with the MIC values of the less susceptible strains. Oral vancomycin is the drug of choice under such circumstances, as its fecal concentration is much higher than that of metronidazole. Copyright (C) 1999 Elsevier Science Inc. |
Persistent Identifier | http://hdl.handle.net/10722/157296 |
ISSN | 2023 Impact Factor: 2.1 2023 SCImago Journal Rankings: 0.626 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wong, SSY | en_US |
dc.contributor.author | Woo, PCY | en_US |
dc.contributor.author | Luk, WK | en_US |
dc.contributor.author | Yuen, KY | en_US |
dc.date.accessioned | 2012-08-08T08:48:44Z | - |
dc.date.available | 2012-08-08T08:48:44Z | - |
dc.date.issued | 1999 | en_US |
dc.identifier.citation | Diagnostic Microbiology and Infectious Disease, 1999, v. 34 n. 1, p. 1-6 | en_US |
dc.identifier.issn | 0732-8893 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/157296 | - |
dc.description.abstract | A prospective study on the susceptibility of Clostridium difficile to metronidazole and vancomycin using the Etest and disk diffusion test was performed over a 6-month period. One hundred strains were tested; one strain was highly resistant to metronidazole (MIC = 64 μg/mL). The zone size of inhibition by the disk diffusion test correlated with the MIC as determined by the Etest (regression coefficient = -0.043 for metronidazole and -0.044 for vancomycin, p < 0.001 for both antibiotics). However, the correlation coefficient was low for both metronidazole (r = 0.574) and vancomycin (r = 0.473); hence the zone of inhibition by disk diffusion test could not predict the MIC satisfactorily. Metronidazole is still the first-line antibiotic for the treatment of C. difficile-associated diarrhea because the incidence of metronidazole resistant strains remains very low. However, the efficacy of metronidazole in the treatment of infections attributable to isolates with high-level metronidazole resistance may be compromised because the fecal concentration of metronidazole is relatively low when compared with the MIC values of the less susceptible strains. Oral vancomycin is the drug of choice under such circumstances, as its fecal concentration is much higher than that of metronidazole. Copyright (C) 1999 Elsevier Science Inc. | en_US |
dc.language | eng | en_US |
dc.publisher | Elsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/diagmicrobio | en_US |
dc.relation.ispartof | Diagnostic Microbiology and Infectious Disease | en_US |
dc.rights | Diagnostic Microbiology and Infectious Disease. Copyright © Elsevier Inc. | - |
dc.subject.mesh | Anti-Bacterial Agents - Pharmacology | en_US |
dc.subject.mesh | Clostridium Difficile - Drug Effects - Growth & Development | en_US |
dc.subject.mesh | Diarrhea - Microbiology | en_US |
dc.subject.mesh | Drug Resistance, Microbial | en_US |
dc.subject.mesh | Enterocolitis, Pseudomembranous - Microbiology | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Metronidazole - Pharmacology | en_US |
dc.subject.mesh | Microbial Sensitivity Tests - Methods | en_US |
dc.subject.mesh | Prospective Studies | en_US |
dc.subject.mesh | Vancomycin - Pharmacology | en_US |
dc.title | Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and E-test | en_US |
dc.type | Article | en_US |
dc.identifier.email | Wong, SSY: samsonsy@hkucc.hku.hk | en_US |
dc.identifier.email | Woo, PCY: pcywoo@hkucc.hku.hk | en_US |
dc.identifier.email | Yuen, KY: kyyuen@hkucc.hku.hk | en_US |
dc.identifier.authority | Wong, SSY=rp00395 | en_US |
dc.identifier.authority | Woo, PCY=rp00430 | en_US |
dc.identifier.authority | Yuen, KY=rp00366 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/S0732-8893(98)00139-4 | en_US |
dc.identifier.pmid | 10342100 | - |
dc.identifier.scopus | eid_2-s2.0-0032939481 | en_US |
dc.identifier.hkuros | 46198 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0032939481&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 34 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.spage | 1 | en_US |
dc.identifier.epage | 6 | en_US |
dc.identifier.isi | WOS:000080305100001 | - |
dc.publisher.place | United States | en_US |
dc.identifier.scopusauthorid | Wong, SSY=13310021400 | en_US |
dc.identifier.scopusauthorid | Woo, PCY=7201801340 | en_US |
dc.identifier.scopusauthorid | Luk, WK=7005237832 | en_US |
dc.identifier.scopusauthorid | Yuen, KY=36078079100 | en_US |
dc.identifier.issnl | 0732-8893 | - |